Recent Finacing
Recent Raise
CEVEC develops proprietary human suspension cell‑line platforms (ELEVECTA, CAP, CAP‑Go) to enable stable, helper‑virus‑free, suspension‑based industrial‑scale production of AAV, adenoviral/lentiviral vectors and complex glycosylated proteins.
